OnKure Net Income from 2010 to 2026
| OKUR Stock | 3.19 0.05 1.59% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -47.4 M | Current Value -49.8 M | Quarterly Volatility 12.4 M |
Check OnKure Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OnKure Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 799.4 K, Other Operating Expenses of 39.7 M or Research Development of 32.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.04. OnKure financial statements analysis is a perfect complement when working with OnKure Therapeutics Valuation or Volatility modules.
OnKure | Net Income | Build AI portfolio with OnKure Stock |
Latest OnKure Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of OnKure Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in OnKure Therapeutics financial statement analysis. It represents the amount of money remaining after all of OnKure Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is OnKure Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OnKure Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (52.67 M) | 10 Years Trend |
|
Net Income |
| Timeline |
OnKure Net Income Regression Statistics
| Arithmetic Mean | (27,562,511) | |
| Coefficient Of Variation | (44.91) | |
| Mean Deviation | 10,479,132 | |
| Median | (19,465,000) | |
| Standard Deviation | 12,379,055 | |
| Sample Variance | 153.2T | |
| Range | 33.2M | |
| R-Value | (0.82) | |
| Mean Square Error | 54.2T | |
| R-Squared | 0.67 | |
| Significance | 0.000061 | |
| Slope | (2,004,053) | |
| Total Sum of Squares | 2451.9T |
OnKure Net Income History
Other Fundumenentals of OnKure Therapeutics
About OnKure Therapeutics Financial Statements
OnKure Therapeutics shareholders use historical fundamental indicators, such as Net Income, to determine how well the company is positioned to perform in the future. Although OnKure Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in OnKure Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on OnKure Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Pair Trading with OnKure Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OnKure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OnKure Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against OnKure Stock
| 0.46 | AMGN | Amgen Inc | PairCorr |
| 0.45 | GILD | Gilead Sciences | PairCorr |
| 0.38 | ABBV | AbbVie Inc | PairCorr |
| 0.38 | TRV | The Travelers Companies Earnings Call This Week | PairCorr |
| 0.31 | JNJ | Johnson Johnson Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to OnKure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OnKure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OnKure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OnKure Therapeutics to buy it.
The correlation of OnKure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OnKure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OnKure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for OnKure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for OnKure Stock Analysis
When running OnKure Therapeutics' price analysis, check to measure OnKure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OnKure Therapeutics is operating at the current time. Most of OnKure Therapeutics' value examination focuses on studying past and present price action to predict the probability of OnKure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OnKure Therapeutics' price. Additionally, you may evaluate how the addition of OnKure Therapeutics to your portfolios can decrease your overall portfolio volatility.